SCHEMBL4207489

SCHEMBL4207489

COc1ccc(NS(=O)(=O)c2ccc(F)cc2)c2c1C[C@@H](N(C)C)CC2

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 8/20 0.57
QRFPR Q96P65 1/20 0.57
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
ALDH1A1 P00352 4/20 0.47
DRD2 P14416 2/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
KDM4E B2RXH2 2/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HSD11B1 P28845 1/20 0.42
HSD17B2 P37059 1/20 0.42
HTR1A P08908 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4197797 0.91 HTR6 (0.59) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4205721 0.90 HTR6 (0.58) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4205977 0.90 HTR6 (0.58) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4201649 0.90 HTR6 (0.58) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4209413 0.90 HTR6 (0.58) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4213931 0.90 HTR6 (0.56) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4204559 0.89 HTR6 (0.68) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4202828 0.89 HTR6 (0.57) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4207178 0.89 HTR6 (0.65) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4197775 0.89 HTR6 (0.60) HTR6QRFPRCHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885CHRM2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.